NEW YORK, May 6, 2016 /PRNewswire-USNewswire/ -- The Galien Foundation invites all pharmaceutical, biotechnology and medical technology companies with products approved by the Food and Drug Administration (FDA) in the five years that ended on December 31, 2015, to submit entries for the 2016 Prix Galien USA Awards. Prizes are awarded for products and agents that improve the human condition after they have been approved for marketing and are benefitting patients.
Judging for this high honor – considered the Nobel Prize of the biopharmaceutical and medical technology industries – will be by a group of highly accomplished individuals from the scientific and research communities, including four Nobel prize winners.
The Foundation's annual Forum will be held at the Alexandria Center for Life Science in New York on Thursday, October 27, 2016, and will feature round table discussions focusing on critical global healthcare issues and challenges. The Prix Galien USA Award ceremony will follow that evening at the American Museum of Natural History.
"The Galien Foundation brings the top scientists in the world, it's an event where you have Nobel laureates across the spectrum of scientific disciplines meeting and talking with members of the pharmaceutical industry to see what's going on at the cutting edge, because ultimately that's going to benefit patients," said William N. Hait, M.D., PH.D., Global Head, Research and Development at Janssen, the pharmaceutical companies of Johnson & Johnson. "It was an incredible honor to be a Prix Galien Award recipient last year, as it is our industry's highest accolade. The level of innovations being presented at the Forum and awarded by the Galien Foundation are second to none, and I am looking forward to this year's program."
2016 marks the 10th year of the Prix Galien USA Awards program. To celebrate the participating companies' leadership in confirming this past decade as one of history's most productive for research, the Committee will select one product from each of the three award categories as the "Discovery of the Decade." Nominations for this award are open to every medicine and medical technology that the Awards Committee selected as the category winner in previous annual honors – 34 products in all, including the 2016 Prix Galien USA Laureates.
"We are continually amazed by the work of those in the medical field who are tireless in their efforts to improve the lives of patients across the globe and who are developing disruptive therapies and technologies to tackle disease," said Bruno Cohen, Chairman of the Galien Foundation. "This year, as always, we look forward to recognizing those who, through their dedication and perseverance, are making such important contributions to the field of medical innovation."
About the Galien Foundation
The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatment and technologies that will impact human health and save lives.
The Foundation oversees and directs activities in the USA for the Prix Galien, an international award that recognizes outstanding achievements in improving the human condition through the development of innovative therapies. The Prix Galien was created in France in 1970 in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical and medical technology research.
For more information, visit www.galienfoundation.org.
CONTACT: Galien Foundation, 212-685-1592
SOURCE The Galien Foundation